Basilea Pharmaceutica AG (BSLN.S) News| Reuters.com
Edition:
United States

Basilea Pharmaceutica AG (BSLN.S)

BSLN.S on Swiss Exchange

62.95CHF
7:19am EDT
Change (% chg)

CHF-3.35 (-5.05%)
Prev Close
CHF66.30
Open
CHF66.30
Day's High
CHF66.45
Day's Low
CHF62.70
Volume
38,766
Avg. Vol
64,614
52-wk High
CHF126.50
52-wk Low
CHF58.80

Select another date:

BRIEF-Basilea Pharmaceutica: CRESEMBA (isavuconazole) launched in Italy

* Basilea's antifungal CRESEMBA (isavuconazole) launched in Italy Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Basilea Pharmaceutica presents data on clinical oncology programs BAL101553 and BAL3833

* Reports presentation of data on clinical oncology programs BAL101553 AND BAL3833 at Asco meeting

BRIEF-Basilea Pharmaceutica presents data on clinical oncology programs BAL101553 and BAL3833

* Reports presentation of data on clinical oncology programs BAL101553 and BAL3833 at AACR meeting

BRIEF-Basilea Pharmaceutica wins contract by BARDA of up to $100 mln funding for Ceftobiprole phase 3 program

* Basilea awarded contract by BARDA of up to $100 million funding for Ceftobiprole phase 3 program Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Basilea Pharmaceutica nominates Domenico Scala as new chairman of board

* Martin Nicklasson has determined not to stand for re-election as chairman but will stand for re-election as member of board

Swiss Basilea says profits still 2-3 years away

ZURICH Swiss drugmaker Basilea expects to move into profit by 2018, counting on new anti-infection drugs to help mitigate setbacks such as last month's collapse of efforts to win U.S. approval for an eczema treatment.

Swiss Basilea says profits still 2-3 years away

* GSK dumped U.S. approval bid for Basilea skin drug in January

BRIEF-Basilea Pharmaceutica FY 2015 contract revenue up at CHF 51.2 mln

* FY contract revenue 2015 amounted to 51.2 million Swiss francs ($51.43 million)(2014: 42.1 million Swiss francs)

Actelion CEO says Basilea purchase would make no sense: paper

ZURICH Swiss drug maker Actelion's chief executive quashed speculation over its possible interest in purchasing Basilea Pharmaceutica.

Actelion CEO says Basilea purchase would make no sense -paper

ZURICH, Jan 15 Swiss drug maker Actelion's chief executive quashed speculation over its possible interest in purchasing Basilea Pharmaceutica.

Select another date: